Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Prostate ; 66(13): 1381-90, 2006 Sep 15.
Article in English | MEDLINE | ID: mdl-16804886

ABSTRACT

In prostate cancer progression, the basal lamina switches from predominantly laminin-5 to laminin-10. DU-145 prostate cancer cells were treated with either soluble laminin-5 (20 ng/ml) or laminin-10 (1 microg/ml) for 6, 24, and 48 hr. Total RNA was harvested for a 7,500 human cDNA microarray. Hybridizations were carried out in accordance with a 10 sample analysis of variance (ANOVA) statistical model. One thousand one hundred sixteen genes had measurable expression 2 standard deviations above background and 50% of spots for any given sample for all hybridizations were positive. Expression values of significantly varying genes were clustered and a list of 408 genes (P < 0.05) with a 1.5 or greater fold change in at least one time point were chosen for further analysis. Seventy eight changed in a time-dependent manner with laminin-10 treatment, 85 changed with laminin-5, and 13 showed changes with both treatments. The 408 genes that passed a paired t-test in at least one time-dependent category were further analyzed using Pathway Miner. One of the largest gene association networks involved signal transduction in the growth factor-MAP kinase pathways. EGFR was validated by real-time PCR and laminin-10 mediated cell adhesion activated EGFR in DU-145 cells. Both laminins appear to be important signal transducers in prostate cancer.


Subject(s)
Cell Adhesion Molecules/physiology , Gene Expression Regulation, Neoplastic/drug effects , Laminin/physiology , Prostatic Neoplasms/genetics , Calpain/genetics , Calpain/metabolism , Cell Line, Tumor , DNA, Neoplasm/genetics , ErbB Receptors/genetics , ErbB Receptors/metabolism , Gene Expression Profiling , Gene Expression Regulation, Neoplastic/genetics , Humans , MAP Kinase Signaling System/genetics , Male , Oligonucleotide Array Sequence Analysis , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , RNA, Neoplasm/genetics , Signal Transduction/genetics , Time Factors , Kalinin
2.
Prostate ; 66(3): 283-93, 2006 Feb 15.
Article in English | MEDLINE | ID: mdl-16245278

ABSTRACT

BACKGROUND: 90K/Mac-2 binding protein is a cell adhesive protein whose level of expression has been correlated with metastatic potential in many different tumor types. The purpose of this investigation was to examine 90K expression in prostate cancer and to determine a possible role for 90K in cancer progression. METHODS: 90K expression in prostate cell lines and tissue samples was evaluated by immunohistochemistry. Expression in cell lines was also evaluated by Western blot analysis and real-time RT-PCR. Induction of promatrilysin by 90K was evaluated by ELISA. RESULTS: Some of the human prostate cell lines studied expressed 90K. 90K was over-expressed in 38.8% of prostate cancer tumor samples, 7.14% of PIN lesions, and 18.6% of normal tissue. 90K was also shown to induce promatrilysin expression in the prostate cell line, LNCaP. CONCLUSIONS: These data demonstrate that 90K is over-expressed in a large fraction of malignant tumors. The fact that 90K can induce expression of promatrilysin indicates a possible role for 90K in cancer progression and metastasis. This suggests that 90K over-expression may be a useful marker for examining prostate cancer progression.


Subject(s)
Antigens, Neoplasm/biosynthesis , Enzyme Precursors/biosynthesis , Membrane Glycoproteins/biosynthesis , Metalloendopeptidases/biosynthesis , Prostatic Neoplasms/metabolism , Antigens, Neoplasm/genetics , Antigens, Neoplasm/metabolism , Blotting, Western , Cell Line, Tumor , Disease Progression , Enzyme Precursors/genetics , Enzyme Precursors/metabolism , Enzyme-Linked Immunosorbent Assay , HT29 Cells , Humans , Immunohistochemistry , Male , Mass Spectrometry , Matrix Metalloproteinase 7/biosynthesis , Matrix Metalloproteinase 7/genetics , Membrane Glycoproteins/genetics , Membrane Glycoproteins/metabolism , Metalloendopeptidases/genetics , Metalloendopeptidases/metabolism , Predictive Value of Tests , Prostate-Specific Antigen/blood , Prostatic Neoplasms/enzymology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , RNA, Neoplasm/chemistry , RNA, Neoplasm/genetics , Reverse Transcriptase Polymerase Chain Reaction
3.
Neoplasia ; 7(4): 380-9, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15967115

ABSTRACT

Disruption of the extracellular matrix by proteases is crucial for tumor invasion. Laminin-10 (Ln-10) has previously been identified as a substrate for cell migration and cell adhesion, and is present in the basal lamina (BL) of both normal prostate and prostate cancer. Here, we investigate a role for membrane type 1 matrix metalloprotease (MT1-MMP) in modifying this Ln-10-rich BL. MT1-MMP is a transmembrane member of the MMP family that has been demonstrated to be upregulated as prostate cancer progresses from normal to prostate intraepithelial neoplasia to invasive cancer, suggesting a role for MT1-MMP in the invasion of prostate cancer. We show that MT1-MMP cleaves the alpha5 chain of purified human Ln-10 from its 350-kDa form into 310-, 190-, 160-, and 45-kDa fragments. This cleavage causes a decrease in DU-145 prostate cancer cell adhesion to purified Ln-10, and an increase in transmigration of DU-145 cells through cleaved Ln-10. We also show that prostate cancer cells expressing membrane-bound MT1-MMP cleave the alpha5 chain of Ln-10. Ln alpha5-chain cleavage is also observed in human prostate cancer tissues. These findings suggest that prostate cancer cells expressing high levels of MT1-MMP have increased invasive potential through their ability to degrade and invade Ln-10 barriers.


Subject(s)
Laminin/metabolism , Metalloendopeptidases/physiology , Prostatic Neoplasms/metabolism , Cell Adhesion , Cell Line, Tumor , Cell Membrane/metabolism , Cell Movement , Culture Media, Conditioned/metabolism , Culture Media, Conditioned/pharmacology , Culture Media, Serum-Free/pharmacology , Humans , Immunohistochemistry , Male , Mass Spectrometry , Matrix Metalloproteinases, Membrane-Associated , Metalloendopeptidases/metabolism , Models, Biological , Models, Genetic , Neoplasm Invasiveness , Prostatic Neoplasms/pathology , Time Factors
4.
Mol Carcinog ; 38(2): 70-7, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14502646

ABSTRACT

Previously we have shown that the matrix metalloproteinase matrilysin (MMP-7) is overexpressed in human prostate cancers compared with normal epithelium. However, the mechanism for this overexpression is not understood. Human prostate fibroblasts have been shown to express certain fibroblast growth factors (FGFs), including FGF-1. Evidence from our laboratory and others has indicated that FGFs can regulate the expression of certain matrix metalloproteinases, including matrilysin. The goal of this study was to determine whether pharmacological inhibition of FGFR signaling would alter LNCaP tumor growth as well as expression of promatrilysin when LNCaP cells were co-injected subcutaneously with human prostate fibroblasts into athymic nude mice. For these inhibitor studies, AG1-X2 beads were coated with the pharmacological FGFR inhibitor SU5402 and were co-injected along with LNCaP and human prostate fibroblast cells (PF). Mice injected with LNCaP/PF and LNCaP/PF/beads alone demonstrated significant tumor growth, whereas mice injected with LNCaP/PF/SU5402-coated beads showed a significant decrease in tumor volume and weight. Immunohistochemical analysis showed that significant promatrilysin expression in tumors was inhibited by the FGFR inhibitor SU5402. Serum prostate-specific antigen (PSA) and promatrilysin levels were measured by enzyme-linked immunosorbent assay. The mice injected with LNCaP/PF and LNCaP/PF/beads expressed promatrilysin and serum PSA levels that were inhibited by co-injecting with SU5402. Therefore, pharmacological inhibition of FGF receptor signaling results in a decrease in the growth of LNCaP tumors generated subcutaneously by co-injecting LNCaP cells and human prostate fibroblasts. The inhibition in tumor growth was correlated with a decrease in tumor promatrilysin expression and a decrease in serum promatrilysin and PSA.


Subject(s)
Prostate-Specific Antigen/metabolism , Prostatic Neoplasms/prevention & control , Receptors, Fibroblast Growth Factor/antagonists & inhibitors , Animals , Carcinoma/metabolism , Carcinoma/pathology , Carcinoma/prevention & control , Enzyme Precursors/metabolism , Humans , Male , Metalloendopeptidases/metabolism , Mice , Mice, Nude , Neoplasm Transplantation , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Pyrroles , Transplantation, Heterologous , Tumor Cells, Cultured
5.
Cancer Res ; 63(9): 2292-9, 2003 May 01.
Article in English | MEDLINE | ID: mdl-12727852

ABSTRACT

Degradation of the extracellular matrix by proteolytic enzymes is a central aspect of physiological and pathologic tissue-remodeling processes such as trophoblastic implantation, wound healing, and tumor invasion. We have hypothesized that prostate adenocarcinoma cell invasion through the normal basal lamina is attributable in part to metalloproteinase-induced cleavage of laminin-5 (Ln-5) and enhanced motility of the cancer cells. We studied the role of membrane type-1-matrix metalloproteinase (MT1-MMP) expressed on the surface of prostate tumor cells in cleaving Ln-5 and enhancing the migration of prostate tumor cells. We also determined the nature of the MT1-MMP cleavage of human Ln-5 and how this altered Ln-5 changes the migration of prostate carcinoma cells. We found that human MT1-MMP cleaves purified human Ln-5 to an 80-kDa fragment. Mass spectrometry analyses of the 80-kDa cleaved product by trypsin and chymotrypsin gave 14 and 9 different peptide sequences, respectively, that were identical to the expected amino acid sequence of the Ln-5-beta3 chain. The recovered peptides represent 14.4% (trypsin) and 10.3% (chymotrypsin) of Ln-5-beta3 chain by amino acid count. Both trypsin and chymotrypsin digestion of MT1-MMP-cleaved product of Ln-5 did not show any other peptides that were identical to the other chains of Ln-5. Using a linear migration assay we found that the Ln-5 cleaved by MT1-MMP enhanced the migration of DU-145 prostate carcinoma cells by 2-fold compared with uncleaved Ln-5. The use of blocked antisense MT1-MMP oligonucleotides inhibited the migration of DU-145 cells on Ln-5. We also found that the prostate carcinoma cells expressing high levels of MT1-MMP, such as PC3N and PPC, demonstrated enhanced migration on human Ln-5-coated substrate, and this migration was inhibited using blocked antisense MT1-MMP oligonucleotides. In conclusion, this is a novel and important finding where we have shown that beta3-chain is cleaved by MT1-MMP, and this cleavage enhances migration of prostate cancer cells.


Subject(s)
Cell Adhesion Molecules/metabolism , Cell Movement/physiology , Metalloendopeptidases/metabolism , Prostatic Neoplasms/enzymology , Prostatic Neoplasms/pathology , Amino Acid Sequence , Antibodies, Monoclonal/immunology , Antibody Specificity , Cell Adhesion Molecules/immunology , Humans , Male , Matrix Metalloproteinases, Membrane-Associated , Metalloendopeptidases/biosynthesis , Metalloendopeptidases/pharmacology , Molecular Sequence Data , Neoplasm Invasiveness , Prostatic Neoplasms/metabolism , Recombinant Proteins/pharmacology , Tumor Cells, Cultured , Kalinin
SELECTION OF CITATIONS
SEARCH DETAIL
...